Division of Boston Scientific Corp.
Latest From Vertiflex Inc.
Vertiflex sells the Superion indirect decompression system, a minimally invasive device to treat lumbar spinal stenosis. Boston Scientific expects it to bring in $60m in revenue in 2019 to its Neuromodulation business.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Vertos Medical asked the US Medicare agency to reconsider its 2014 decision that limits coverage of percutaneous image-guided lumbar decompression for lumbar spine stenosis to certain clinical trials. The agency ruled Dec. 7 that it will stick with the trial-limited policy, but expanded it to include longitudinal studies.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
Earl R Fender, Pres. & CEO
Jeffrey A Swiecki, SVP, CFO
Stephen R Reitzler, VP, Clinical & RA
JP Timm, VP, Ops. & Dev.
Michael Enxing, VP, Chief Commercial Officer
Sean Patrick, VP, Chief Marketing Officer
- Contact Info
Phone: (442) 325-5900
2714 Loker Ave. West, Ste. 100
Carlsbad, CA 92010
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.